Eli Lilly and Company Q2 Earnings Call Highlights
Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.
How this was made
The 30-second read
Why it matters
Traders can update FY 2026 expectations using the raised revenue, margin, and EPS ranges, then reassess near-term demand sensitivity to Medicare coverage and the probability/timing of future oral and injectable obesity/diabetes launches.
Market read
A guidance raise with quantified ranges plus multiple incremental catalysts (coverage expansion, Phase III retatrutide results, and several regulatory updates) makes this a meaningful repricing event for LLY positioning.
What to watch
The guidance explicitly incorporates prior-period rebate/discount estimate adjustments and seasonality effects, which may limit how much of the raise is durable versus accounting/seasonal normalization.
Background
The piece summarizes Eli Lilly’s Q2 earnings call, focusing on revenue drivers, guidance, demand trends for Zepbound and Mounjaro, Medicare coverage changes, pipeline milestones, and business development/manufacturing updates.
Ticker impact
Lilly raised full-year 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS to $35.50-$36.50 on the Q2 call.
Moderately positive bias for the next session and subsequent days as traders reprice FY 2026 revenue, margin, and EPS expectations.
The article contains a concrete guidance increase with quantified ranges, plus multiple incremental catalysts (launch coverage expansion, Phase III readouts, and regulatory approvals/opinions). While it is a call highlights recap, the guidance numbers are primary decision inputs for positioning.
Market effects
Reinforces GLP-1 and broader obesity/incretin demand momentum and supports sentiment for large-cap pharma with obesity franchises.
Highlights strong international growth (Europe, Japan, China, rest of world), which can influence regional pharma demand expectations.
Medicare GLP-1 coverage expansion and retatrutide registration plans can affect global competitive dynamics in obesity and diabetes markets.
Counterpoint
Raised guidance may already reflect known demand trends; margin and rebate/discount estimate dynamics could introduce volatility in quarterly comparisons.
Key entities
- companyEli Lilly and Company
Raised FY 2026 revenue and non-GAAP EPS guidance; discussed GLP-1 demand, Medicare GLP-1 Bridge Program impact, retatrutide Phase III data, and multiple regulatory/pipeline milestones.
